Robert M. Krug

The University of Texas at Austin — United States

Medicine · Health Sciences

80h-index17.9kcitations220works8.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Influenza Virus Research Studies(105), interferon and immune responses(83), RNA and protein synthesis mechanisms(73), Respiratory viral infections research(42), Virus-based gene therapy research(38)

Publications220 total

A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients
eLife·2024· 10 citedOpen Access
The NS1 protein of influenza B virus binds 5’-triphosphorylated dsRNA to suppress RIG-I activation and the host antiviral response
2024Open Access
Author response: A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients
2024Open Access
Public Health Impact of Paxlovid as Treatment for COVID-19, United States
Emerging infectious diseases·2024· 23 citedOpen Access
The NS1 protein of influenza B virus binds 5’-triphosphorylated dsRNA to suppress RIG-I activation and the host antiviral response
2023· 4 citedOpen Access
The public health impact of Paxlovid COVID-19 treatment in the United States
2023Open Access
Structural similarities between SARS-CoV2 3CLpro and other viral proteases suggest potential lead molecules for developing broad spectrum antivirals
Frontiers in Chemistry·2022· 16 citedOpen Access
Structure function characterization of SARS CoV2 proteases for COVID19 antiviral development
Biophysical Journal·2022Open Access
Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture
Cell Reports·2021· 78 citedOpen Access
Hepatitis C Virus Protease Inhibitors Suppress Virus Replication and Act Synergistically with the SARS-CoV2 Polymerase Inhibitor Remdesivir
Biophysical Journal·2021Open Access
Hepatitis C Virus Drugs Simeprevir and Grazoprevir Synergize with Remdesivir to Suppress SARS-CoV-2 Replication in Cell Culture
2020· 9 citedOpen Access
Modeling mitigation of influenza epidemics by baloxavir
Nature Communications·2020· 63 citedOpen Access
Structural Similarity of SARS-CoV2 Mpro and HCV NS3/4A Proteases Suggests New Approaches for Identifying Existing Drugs Useful as COVID-19 Therapeutics
2020· 46 citedOpen Access
Structural Similarity of SARS-CoV2 Mpro and HCV NS3/4A Proteases Suggests New Approaches for Identifying Existing Drugs Useful as COVID-19 Therapeutics
2020· 57 citedOpen Access
A realistic flow phantom model of the carotid artery in preterm infants for training and research
Ultrasound·2020· 2 citedOpen Access
Hepatitis C Virus Drugs Simeprevir And Grazoprevir Synergize with Remdesivir to Suppress SARS-CoV2 Replication
SSRN Electronic Journal·2020Open Access
A double-stranded RNA platform is required for the interaction between a host restriction factor and the NS1 protein of influenza A virus
Nucleic Acids Research·2019· 18 citedOpen Access
Safe-To-Explore State Spaces: Ensuring Safe Exploration in Policy Search\n with Hierarchical Task Optimization
arXiv (Cornell University)·2018Open Access
Avian Influenza Virus PB1 Gene in H3N2 Viruses Evolved in Humans To Reduce Interferon Inhibition by Skewing Codon Usage toward Interferon-Altered tRNA Pools
mBio·2018· 37 citedOpen Access
wilkelab/influenza_codon_usage: Influenza Codon Usage
Zenodo (CERN European Organization for Nuclear Research)·2018Open Access
page 1 of 11Next →

Frequent Co-authors

Chen Zhao(6), Karen Y. Twu(5), G.T. Montelione(5), Rei-Lin Kuo(5), Michèle Bouloy(4), Chen-ya Chien(4), Stephen J. Plotch(3), Ismo Ulmanen(3), Yongzhong Li(3), Jon M. Huibregtse(3), James M. Aramini(3), Diana L. Noah(3), B Broni(3), Tien-Ying Hsiang(3), Geoffrey I. Shapiro(3), M E Nemeroff(2), Yizhi Jane Tao(2), Michael G. Katze(2), Shoudong Li(2), Ji-Young Min(2)